Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities:
Net earnings (loss)	$ (162,857)	$ (146,398)	$ 158,519
Cash flows from operating activities:
Depreciation of property and equipment	12,537	12,758	8,953
Amortization and impairment of intangible assets	78,312	11,637	18,890
Amortization of operating lease right-of-use assets	6,149	6,499	5,259
Stock-based compensation	67,581	64,183	49,481
Fair value (gain) loss on contingent consideration and investments	(64,727)	(8,018)	3,091
Other	(19,708)	2,237	3,342
Changes in operating assets and liabilities:
Research fee and grant receivable	(75,119)	(45,933)	(22,715)
Accrued royalties receivable	0	9,273	129,171
Income taxes (payable) receivable	6,651	30,464	(88,609)
Accounts payable and accrued liabilities	10,635	(15,104)	(2,094)
Deferred revenue	(7,931)	(13,976)	6,183
Deferred grant income	33,967	39,521	9,264
Other assets	5,954	8,980	(1,375)
Net cash provided by (used in) operating activities	(108,556)	(43,877)	277,360
Cash flows from investing activities:
Purchases of property and equipment	(78,396)	(76,947)	(70,660)
Purchase of intangible assets	0	(560)	(2,000)
Purchase of marketable securities	(765,086)	(1,021,510)	(763,982)
Proceeds from marketable securities	937,882	910,937	510,631
Receipt of grant funding	35,708	25,311	16,434
Long-term investments and other assets	10,927	(44,649)	(17,369)
Investment in and loans to equity accounted investees	(19,626)	(13,690)	(25,679)
Net cash provided by (used in) investing activities	121,409	(221,108)	(352,625)
Cash flows from financing activities:
Payment of liability for in-licensing agreement and other	(729)	(1,234)	(4,383)
Proceeds from long-term liabilities and exercise of stock options	13,498	11,590	2,755
Net cash provided by (used in) financing activities	12,769	10,356	(1,628)
Effect of exchange rate changes on cash and cash equivalents	(2,617)	589	(9,599)
Increase (decrease) in cash and cash equivalents	23,005	(254,040)	(86,492)
Cash and cash equivalents and restricted cash, beginning of period	160,610	414,650	501,142
Cash and cash equivalents and restricted cash, end of period	183,615	160,610	414,650
Restricted cash included in other assets	2,290	2,290	3,115
Total cash, cash equivalents, and restricted cash shown on the balance sheet	181,325	158,320	411,535
Supplemental disclosure of non-cash investing and financing activities
Property and equipment in accounts payable	12,767	13,625	5,868
Right-of-use assets obtained in exchange for operating lease obligation	$ 1,898	$ 1,199	$ 50,694